SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc.'s next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, SELLAS Life Sciences Group, Inc. has 201.92M shares outstanding.

As of June 30, 2026, SELLAS Life Sciences Group, Inc. maintains a current ratio of 18.83, meaning it holds 18.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, SELLAS Life Sciences Group, Inc. posted a negative return on equity (ROE) of -39.63, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -36.54, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 13.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, SELLAS Life Sciences Group, Inc. generated - - in revenue and converted that into -28.41M in net income, yielding earnings per share of -0.18. EBITDA reached -30.83M, while operating income came in at -30.83M.

As of June 30, 2026, SELLAS Life Sciences Group, Inc. holds 121.09M in cash and equivalents against 645,096.10 in total debt, resulting in a net debt position of -121.09M. Total book value stands at 120.49M, with working capital of 118.11M providing operational flexibility.

SELLAS Life Sciences Group, Inc. produced -24.88M in operating cash flow over the twelve months ended June 30, 2026.

SELLAS Life Sciences Group, Inc.'s most recent stock split took place on November 8, 2019 with a 50:1 split ratio.